Literature DB >> 6155268

Comparison of 67Ga-citrate, 111In-bleomycin and 99mTc-citrate in the evaluation of pulmonary lesions.

P Apostolidis, P Kostaki, N Hatzigeorgiou, N Skambardonis, J Giavroglou, N Salem.   

Abstract

A total of 128 patients were examined using three tumor localizing agents, 99mTc-citrate, 111In-bleomycin and 67Ga-citrate. All these patients had clinical symptoms of pulmonary disease and chest x-rays. Twenty-two patients were excluded from the original number. From the 106 remaining patients, 14 were benign cases and 92 malignant. A scan with a gamma-camera was performed 3 to 4 h following an intravenous injection of 15 mCi of 99mTc-citrate. Upon completion of this examination, the patient was given 2.5 mCi of 67Ga-citrate and 72 h later, scans were obtained using a 5in. rectilinear scanner. Fifteen days later 2.5 mCi of 111In-bleomycin was given and a similar examination to that of gallium was performed. In evaluating benign lesions, 99mTc-citrate gave no false positive results, while 111In-bleomycin gave 5% and 67Ga-citrate 20%. In the case of malignant lesions, 67Ga-citrate gave 79% true positive diagnosis, 111In-bleomycin 65% and 99Tc-citrate (of 57 evaluated patients) 46%.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6155268     DOI: 10.1007/BF00261208

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  18 in total

1.  67Ga-citrate imaging in untreated malignant lymphoma: preliminary report of Cooperative Group.

Authors:  R H Greenlaw; M B Weinstein; A B Brill; J K McBain; L Murphy; R M Kniseley
Journal:  J Nucl Med       Date:  1974-06       Impact factor: 10.057

2.  Bleomycin as a 99mTc carrier in tumor visualization.

Authors:  M S Lin; D A Goodwin; S L Kruse
Journal:  J Nucl Med       Date:  1974-05       Impact factor: 10.057

3.  Scanning malignant neoplasms with gallium 67.

Authors:  C L Edwards; R L Hayes
Journal:  JAMA       Date:  1970-05-18       Impact factor: 56.272

4.  The use of 67 Ga scanning in the staging of Hodgkin's disease.

Authors:  D A Turner; S M Pinsky; A Gottschalk; P B Hoffer; J E Ultmann; P V Harper
Journal:  Radiology       Date:  1972-07       Impact factor: 11.105

Review 5.  Detection of abscesses by radioactive isotopes and external scanning.

Authors:  M Deysine
Journal:  Surg Gynecol Obstet       Date:  1976-03

6.  A clinical comparison of the tumour-imaging radiopharmaceuticals 67Gallium-citrate and 111Indium-labelled bleomycin.

Authors:  A H Paterson; D M Taylor; V R McCready
Journal:  Br J Radiol       Date:  1975-10       Impact factor: 3.039

7.  Clinical evaluation of radiolabeled bleomycin (BLEO) for tumor detection.

Authors:  R B Grove; R C Reba; W C Eckelman; M Goodyear
Journal:  J Nucl Med       Date:  1974-06       Impact factor: 10.057

8.  111-In-labelled bleomycin; clinical experience as a diagnostic agent in tumours of the thorax and abdomen.

Authors:  M V Merrick; J P Lavender; G W Poole; P Stradling; M L Thakur; L H Walter
Journal:  Br J Radiol       Date:  1975-04       Impact factor: 3.039

9.  Role of gallium 67 in inflammatory disease.

Authors:  E V Staab; W H McCartney
Journal:  Semin Nucl Med       Date:  1978-07       Impact factor: 4.446

10.  Comparison of radiolabeled bleomycins and gallium citrate in tumor-bearing mice.

Authors:  K A Krohn; J M Meyers; G L DeNardo; S J DeNardo
Journal:  J Nucl Med       Date:  1977-03       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.